Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2‐Mercaptoquinazolinone as the Cap Moiety

Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2‐Mercaptoquinazolinone as the Cap Moiety

Show other versions (1)

Epigenetic alterations found in all human cancers are promising targets for anticancer therapy. In this sense, histone deacetylase inhibitors (HDACIs) are interesting anticancer agents that play an important role in the epigenetic regulation of cancer cells. Here, we report 15 novel hydroxamic acid‐...

Full description

Bibliographic Details
Main Authors: Bui, H.T.B (Author), Hong, Q.V (Author), Jung, H. (Author), Le, H.T (Author), Nguyen, P.H (Author), Nguyen, Q.C (Author), Nguyen, Q.P (Author), Pham, Q.M (Author), Tran, D.Q (Author), Tran, H.P (Author), Yang, S.-G (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
2‐mercaptoquinazolinone
anticancer drugs
antineoplastic agent
Antineoplastic Agents
antiproliferative activity
cell proliferation
Cell Proliferation
chemical structure
chemistry
drug screening
Drug Screening Assays, Antitumor
Epigenesis, Genetic
genetic epigenesis
HDAC8 protein, human
histone deacetylase
histone deacetylase 6
Histone Deacetylase 6
histone deacetylase inhibitor
Histone Deacetylase Inhibitors
Histone Deacetylases
human
Humans
hydroxamic acid‐based histone deacetylase inhibitors
metabolism
molecular docking
Molecular Docking Simulation
Molecular Structure
repressor protein
Repressor Proteins
structure activity relation
Structure-Activity Relationship
tubulin acetylation level
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items